Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.

Abstract excerpt

Lung cancer is the leading cause of cancer-related deaths worldwide, and even today, the 5-year survival rate is still below 15%. Lung adenocarcinoma is the most frequent subtype, and approximately 25% of the cases harbor activating mutations in the KRAS gene. To date, there is no effective treatment for patients carrying KRAS mutations due, at least in part, to the challenge posed by direct targeting of the KRAS...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenocarcinoma of Lung
• Share to Cell Cycle
• Share to Drug Evaluation, Preclinical